01—Abstract
Summary
Summary of the 10-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. reported a 5% decrease in revenue for the fiscal year ended December 30, 2023, primarily driven by a significant decline in COVID-19 related sales, which fell from $3.11 billion in 2022 to $0.33 billiona in 2023.
This reduction was partially offset by strong performance in the Analytical Instruments segment and the Laboratory Products and Biopharma Services segment, which saw revenue increases of 10% and 2% respectively on an organic basis. The company also executed significant restructuring actions, incurring $0.2 billionb in charges to streamline operations, which are expected to yield $0.5 billion in annual cost savings. The company continues to focus on its three-pillar growth strategy: high-impact innovation, trusted partner status with customers, and an unparalleled commercial engine.
Strategic acquisitions in 2023 included The Binding Site Group for specialty diagnostics and CorEvitas, LLC for real-world evidence solutions. Thermo Fisher also announced a proposed acquisition of Olink Holding AB for approximately $3.1 billionc to expand its proteomics capabilities, subject to regulatory approvals and tender offer completion.
Despite the revenue decline, the company maintained a strong free cash flow of $7.014 billiond and returned capital to shareholders through share repurchases totaling $3.00 billion and dividend payments. The company ended the year with a robust cash position of $8.077 billion.
02—Key points
Key Highlights
- Total revenues decreased by 5% to $42.86 billion in 2023, largely due to a substantial drop in COVID-19 related revenue from $3.11 billion in 2022 to $0.33 billion in 2023.
- Life Sciences Solutions segment revenue declined by 26% organically, primarily reflecting the moderation in COVID-19 related demand.
- Analytical Instruments segment revenue grew by 10% organically, driven by strength in electron microscopy and chromatography/mass spectrometry.
- Laboratory Products and Biopharma Services segment revenue increased by 2% organically, supported by growth in clinical research and pharma services.
- The company repurchased $3.00 billion of its common stock in 2023 and announced a new authorization for up to $4.00 billion.
- Free cash flow remained strong at $7.014 billion in 2023.
- Thermo Fisher completed two strategic acquisitions in 2023: The Binding Site Group and CorEvitas, LLC.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 22, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $42.86B$44.91B | −4.6% |
| R&D Expenses | $1.34B$1.47B | −9.1% |
| SG&A Expenses | $8.45B$8.99B | −6.1% |
| Operating Expenses | $36.00B$36.52B | −1.4% |
| Operating Income | $6.86B$8.39B | −18.3% |
| Interest Expense | $1.38B$726.00M | +89.4% |
| Net Income | $6.00B$6.95B | −13.7% |
| EPS (Basic) | $15.52$17.75 | −12.6% |
| EPS (Diluted) | $15.45$17.63 | −12.4% |
| Shares Outstanding (Basic) | 386.00M392.00M | −1.5% |
| Shares Outstanding (Diluted) | 388.00M394.00M | −1.5% |
05—Questions
Frequently Asked Questions
What was the main driver for the revenue decline in 2023?
The primary reason for the revenue decline in 2023 was the significant decrease in sales related to COVID-19 testing and therapies, which dropped from $3.11 billion in 2022 to $0.33 billion in 2023. This was a notable impact across several segments, particularly Life Sciences Solutions.
How did Thermo Fisher address declining revenues and manage costs?
Thermo Fisher implemented restructuring actions, including headcount reductions and facility consolidations, incurring approximately $0.2 billion in charges. These actions are expected to generate annual cost savings of approximately $0.5 billion. The company also benefited from strong productivity improvements and pricing realization to mitigate inflationary pressures.
What are the company's key growth strategies and recent strategic moves?
Thermo Fisher's growth strategy is built on three pillars: high-impact innovation, its trusted partner status with customers, and its commercial engine. In 2023, it made strategic acquisitions of The Binding Site Group and CorEvitas, LLC. Furthermore, it announced plans to acquire Olink Holding AB for approximately $3.1 billion to enhance its proteomics capabilities, pending regulatory approvals.
How did the company return capital to shareholders?
In 2023, Thermo Fisher Scientific returned capital to shareholders through share repurchases totaling $3.00 billion and dividend payments. The company announced a new share repurchase authorization of up to $4.00 billion and has $1.00 billion remaining under this authorization as of February 22, 2024.
06—Continue